GIKLY
Price
$6.16
Change
+$0.15 (+2.50%)
Updated
Nov 12 closing price
Capitalization
7.59B
105 days until earnings call
Intraday BUY SELL Signals
NVSEF
Price
$127.10
Change
+$0.78 (+0.62%)
Updated
Nov 12 closing price
Capitalization
250.98B
Intraday BUY SELL Signals
Interact to see
Advertisement

GIKLY vs NVSEF

Header iconGIKLY vs NVSEF Comparison
Open Charts GIKLY vs NVSEFBanner chart's image
Grifols Sa
Price$6.16
Change+$0.15 (+2.50%)
Volume$130
Capitalization7.59B
Novartis AG
Price$127.10
Change+$0.78 (+0.62%)
Volume$520
Capitalization250.98B
GIKLY vs NVSEF Comparison Chart in %
GIKLY
Daily Signal:
Gain/Loss:
NVSEF
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
GIKLY vs. NVSEF commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GIKLY is a Hold and NVSEF is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (GIKLY: $6.16 vs. NVSEF: $127.10)
Brand notoriety: GIKLY and NVSEF are both not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: GIKLY: 87% vs. NVSEF: 4%
Market capitalization -- GIKLY: $7.59B vs. NVSEF: $250.98B
GIKLY [@Pharmaceuticals: Major] is valued at $7.59B. NVSEF’s [@Pharmaceuticals: Major] market capitalization is $250.98B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $910.93B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $98.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GIKLY’s FA Score shows that 1 FA rating(s) are green whileNVSEF’s FA Score has 3 green FA rating(s).

  • GIKLY’s FA Score: 1 green, 4 red.
  • NVSEF’s FA Score: 3 green, 2 red.
According to our system of comparison, NVSEF is a better buy in the long-term than GIKLY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GIKLY’s TA Score shows that 0 TA indicator(s) are bullish while NVSEF’s TA Score has 4 bullish TA indicator(s).

  • GIKLY’s TA Score: 0 bullish, 3 bearish.
  • NVSEF’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, NVSEF is a better buy in the short-term than GIKLY.

Price Growth

GIKLY (@Pharmaceuticals: Major) experienced а -10.18% price change this week, while NVSEF (@Pharmaceuticals: Major) price change was +5.92% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +3.48%. For the same industry, the average monthly price growth was +1.46%, and the average quarterly price growth was +19.41%.

Reported Earning Dates

GIKLY is expected to report earnings on Feb 26, 2026.

Industries' Descriptions

@Pharmaceuticals: Major (+3.48% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVSEF($251B) has a higher market cap than GIKLY($7.59B). GIKLY has higher P/E ratio than NVSEF: GIKLY (19.48) vs NVSEF (17.39). GIKLY (32.514) and NVSEF (32.258) have similar YTD gains . NVSEF has higher annual earnings (EBITDA): 22.7B vs. GIKLY (1.62B). NVSEF has more cash in the bank: 7B vs. GIKLY (566M). GIKLY has less debt than NVSEF: GIKLY (8.82B) vs NVSEF (32.6B). NVSEF has higher revenues than GIKLY: NVSEF (55.2B) vs GIKLY (7.45B).
GIKLYNVSEFGIKLY / NVSEF
Capitalization7.59B251B3%
EBITDA1.62B22.7B7%
Gain YTD32.51432.258101%
P/E Ratio19.4817.39112%
Revenue7.45B55.2B13%
Total Cash566M7B8%
Total Debt8.82B32.6B27%
FUNDAMENTALS RATINGS
GIKLY vs NVSEF: Fundamental Ratings
GIKLY
NVSEF
OUTLOOK RATING
1..100
9028
VALUATION
overvalued / fair valued / undervalued
1..100
25
Undervalued
14
Undervalued
PROFIT vs RISK RATING
1..100
10029
SMR RATING
1..100
8329
PRICE GROWTH RATING
1..100
6149
P/E GROWTH RATING
1..100
9548
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NVSEF's Valuation (14) in the null industry is in the same range as GIKLY (25). This means that NVSEF’s stock grew similarly to GIKLY’s over the last 12 months.

NVSEF's Profit vs Risk Rating (29) in the null industry is significantly better than the same rating for GIKLY (100). This means that NVSEF’s stock grew significantly faster than GIKLY’s over the last 12 months.

NVSEF's SMR Rating (29) in the null industry is somewhat better than the same rating for GIKLY (83). This means that NVSEF’s stock grew somewhat faster than GIKLY’s over the last 12 months.

NVSEF's Price Growth Rating (49) in the null industry is in the same range as GIKLY (61). This means that NVSEF’s stock grew similarly to GIKLY’s over the last 12 months.

NVSEF's P/E Growth Rating (48) in the null industry is somewhat better than the same rating for GIKLY (95). This means that NVSEF’s stock grew somewhat faster than GIKLY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GIKLYNVSEF
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
48%
Stochastic
ODDS (%)
N/A
Bearish Trend 2 days ago
48%
Momentum
ODDS (%)
Bearish Trend 2 days ago
62%
Bearish Trend 2 days ago
52%
MACD
ODDS (%)
Bearish Trend 2 days ago
61%
Bearish Trend 2 days ago
48%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
61%
Bullish Trend 2 days ago
50%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
62%
Bearish Trend 2 days ago
45%
Advances
ODDS (%)
N/A
Bullish Trend 4 days ago
50%
Declines
ODDS (%)
N/A
N/A
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
48%
Aroon
ODDS (%)
Bearish Trend 2 days ago
64%
Bearish Trend 2 days ago
44%
View a ticker or compare two or three
Interact to see
Advertisement
GIKLY
Daily Signal:
Gain/Loss:
NVSEF
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
HFXI32.740.21
+0.63%
NYLI FTSE International Eq Ccy Netrl ETF
BNY10.220.04
+0.39%
BlackRock New York Municipal Income Trust
BKSE111.090.36
+0.33%
BNY Mellon US Small Cap Core Equity ETF
JMID29.670.02
+0.08%
Janus Henderson Mid Cap Growth Alpha ETF
BCOR29.97-0.35
-1.16%
Grayscale Bitcoin Adopters ETF

GIKLY and

Correlation & Price change

A.I.dvisor indicates that over the last year, GIKLY has been closely correlated with GRFS. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if GIKLY jumps, then GRFS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GIKLY
1D Price
Change %
GIKLY100%
+2.38%
GRFS - GIKLY
68%
Closely correlated
-0.46%
GIFOF - GIKLY
27%
Poorly correlated
N/A
GIFLF - GIKLY
25%
Poorly correlated
N/A
ORINY - GIKLY
9%
Poorly correlated
N/A
OPHLY - GIKLY
8%
Poorly correlated
+1.37%
More

NVSEF and

Correlation & Price change

A.I.dvisor tells us that NVSEF and SNYNF have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NVSEF and SNYNF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVSEF
1D Price
Change %
NVSEF100%
+0.62%
SNYNF - NVSEF
27%
Poorly correlated
N/A
SNY - NVSEF
21%
Poorly correlated
+0.44%
NVS - NVSEF
20%
Poorly correlated
+1.37%
KYKOF - NVSEF
7%
Poorly correlated
N/A
GIKLY - NVSEF
6%
Poorly correlated
+2.38%
More